원문정보
초록
영어
Immunotherapy using cytotoxic T lymphocyte (CTL) is researched actively to treat various types of cancers and viral infections. For an efficient therapy, obtaining enough cells is very important. Clinical trials involving the adoptive transfer of antigen-specific CTL have shown that efficacy can be achieved with CTL doses of 107-109 cells per kilogram of body mass.1) To expand sufficient
cells, 10% serum supplemented RPMI1640 media is widely used in research or clinical use. However, all sera contain poorly characterized substances, including growth factors, antibodies, and other immunologically active substances.2) For this reason, a chemically defined serum-free media is preferable for cell culture. Therefore, we organized media components from literature searches of serum-free culture for CTL, and through several culture experiments developed a SFM which results in cell expansion comparable to 10% serum supplemented
media. Our goal is to make a more powerful SFM by adding other supplements to the above SFM, which is to be used as a basal SFM. By using fractional factorial methods we are screening the effective supplements within 4 candidates. After finishing this screening work, the amount of the supplements have to be optimized by another statistical method.